[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100532601":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":31,"centralContacts":36,"locations":45,"responsibleParty":77,"collaborators":31,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":82,"sex":88,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":31,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":103,"overallStatus":48,"whyStopped":31,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"University of Maryland, Baltimore","OTHER",[8,15],{"label":9,"type":6,"description":10,"interventionNames":11},"High impact TMD","Other: TMD Phenotype\n\nTMD participants will be clinically phenotyped into two between-subject groups based on their score on the Graded Chronic Pain Scale (GCPS). This group will have a GCPS grade 2b, 3, and 4.",[12,13,14],"Device: RelieVRx","Device: Sham-VR","Other: No-VR (natural history control)",{"label":16,"type":6,"description":17,"interventionNames":18},"Low impact TMD","Other: TMD Phenotype\n\nTMD participants will be clinically phenotyped into two between-subject groups based on their score on the Graded Chronic Pain Scale (GCPS). This group will have a GCPS grade 0, 1, and 2a",[12,13,14],[20,27,32],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","RelieVRx","Participants will use RelieVRx daily for 20min\u002Fday for 3 weeks",[9,16],[26],"Active-VR",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Sham-VR","Participants will use Sham-VR, consisting of video, images, and sound in a head-mounted display but lack the \"sense of presence\" and immersive features of Active-VR (for example, scene changes with head movement). Participants will use the Sham-VR daily for 20min\u002Fday for 3 weeks",[9,16],null,{"type":6,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"No-VR (natural history control)","Participants will continue regular\u002Fusual care without any VR devices (goggles or audiovisual input)",[9,16],[37,42],{"name":38,"role":39,"phone":40,"phoneExt":31,"email":41},"Research Coordinator","CONTACT","410-706-5975","NRSCollocaLab@umaryland.edu",{"name":43,"role":39,"phone":40,"phoneExt":31,"email":44},"Katia Matychak, MS","katiamatychak@umaryland.edu",[46,65],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Luana Colloca","RECRUITING","Baltimore","Maryland","21201-1512","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-76.61219,39.29038,{"lat":58,"lon":57},[61],{"name":62,"role":39,"phone":63,"phoneExt":31,"email":64},"Luana Colloca, MD,PhD,MS","301-364-8089","Colloca@umaryland.edu",{"facility":66,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":67,"geoPoint":69,"contacts":70},"University of Maryland",{"type":55,"coordinates":68},[57,58],{"lat":58,"lon":57},[71,74],{"name":72,"role":39,"phone":63,"phoneExt":31,"email":73},"Luana Colloca, MD, PhD, MS","colloca@umaryland.edu",{"name":43,"role":39,"phone":75,"phoneExt":31,"email":76},"4107065975","asuhr@umaryland.edu",{"type":78,"investigatorFullName":47,"investigatorTitle":79,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"PRINCIPAL_INVESTIGATOR","Professor","100532601","neural-mechanisms-of-immersive-virtual-reality-in-chronic-pain-vr-tmd-eeg-100532601",false,"NCT06214923","Neural Mechanisms of Immersive Virtual Reality in Chronic Pain (VR TMD EEG)","Neural Mechanisms of Immersive Virtual Reality in Chronic Pain","VR TMD EEG","Inclusion Criteria:\n\n* Age (18-88 years)\n* English speaker (written and spoken)\n* Temporal Mandibular Disorder (TMD) for at least 3 months\n* TMD Grade Chronic Pain Scale (GCPS) ≥ 0\n\nExclusion Criteria:\n\n* Present or past degenerative neuromuscular disease\n* Cardiovascular, neurological diseases, pulmonary abnormalities, kidney disease, liver disease, history of cancer within past 3 years\n* Cervical pain (e.g. stenosis, radiculopathy)\n* Any personal (or family first degree) history of mania, schizophrenia, or other psychoses\n* Severe psychiatric condition (e.g. schizophrenia, bipolar disorders, autism) leading to hospitalization within the last 3 years.\n* Use of Antipsychotics (e.g., Risperdal, Ability and clozaril)Lifetime alcohol\u002Fdrug dependence or alcohol\u002Fdrug abuse in past 3 months\n* Pregnancy or breast feeding\n* Color-blindness\n* Impaired or uncorrected hearing\n* Non-dominant hand\n* Any facial trauma that has occurred in the last 6 weeks\n* History of a severe facial trauma in the last 2-3 months\n* Conditions that would interfere with the VR mask placement (e.g. trauma, burn, infection)\n* Known history of severe motion sickness\n* Non-removable head cover, artificial hair, certain types of braids or dreadlocks\n* History of fainting\n* History of angioedema\n* Failed drug test (testing for opiates, cocaine, methamphetamines, and amphetamines)","ALL","18 Years","88 Years",{"count":92,"type":93},78,"ESTIMATED","INTERVENTIONAL",[96],"NA","This project examines, in chronic pain, the mechanisms of immersive virtual reality compared to the mechanisms of placebo hypoalgesia. The potential of developing new non-pharmacological premises for low-risk interventions for pain management is high.",[99,100,101,102],"Pain","Virtual Reality","Placebo","Temporomandibular Disorder",[104,105,106,107],"TMD volunteers","VR","Clinical Pain","Ecological Momentary Assessment","2026-01-22",{"date":110,"type":111},"2026-01-26","ACTUAL",{"date":113,"type":111},"2024-04-09",{"date":115,"type":93},"2026-11-30",{"name":5,"class":6},2]